1. Home
  2. MRC vs GERN Comparison

MRC vs GERN Comparison

Compare MRC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRC
  • GERN
  • Stock Information
  • Founded
  • MRC 1921
  • GERN 1990
  • Country
  • MRC United States
  • GERN United States
  • Employees
  • MRC N/A
  • GERN N/A
  • Industry
  • MRC Industrial Machinery/Components
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRC Industrials
  • GERN Health Care
  • Exchange
  • MRC Nasdaq
  • GERN Nasdaq
  • Market Cap
  • MRC 1.1B
  • GERN 974.5M
  • IPO Year
  • MRC 2012
  • GERN 1996
  • Fundamental
  • Price
  • MRC $14.71
  • GERN $1.13
  • Analyst Decision
  • MRC Strong Buy
  • GERN Buy
  • Analyst Count
  • MRC 3
  • GERN 8
  • Target Price
  • MRC $15.33
  • GERN $3.71
  • AVG Volume (30 Days)
  • MRC 1.3M
  • GERN 8.6M
  • Earning Date
  • MRC 08-06-2025
  • GERN 08-06-2025
  • Dividend Yield
  • MRC N/A
  • GERN N/A
  • EPS Growth
  • MRC N/A
  • GERN N/A
  • EPS
  • MRC N/A
  • GERN N/A
  • Revenue
  • MRC $2,946,000,000.00
  • GERN $116,293,000.00
  • Revenue This Year
  • MRC $5.01
  • GERN $161.44
  • Revenue Next Year
  • MRC $4.81
  • GERN $53.06
  • P/E Ratio
  • MRC $30.03
  • GERN N/A
  • Revenue Growth
  • MRC N/A
  • GERN 22264.04
  • 52 Week Low
  • MRC $9.23
  • GERN $1.10
  • 52 Week High
  • MRC $15.59
  • GERN $4.89
  • Technical
  • Relative Strength Index (RSI)
  • MRC 62.81
  • GERN 36.27
  • Support Level
  • MRC $14.24
  • GERN $1.09
  • Resistance Level
  • MRC $15.34
  • GERN $1.37
  • Average True Range (ATR)
  • MRC 0.49
  • GERN 0.08
  • MACD
  • MRC 0.08
  • GERN -0.01
  • Stochastic Oscillator
  • MRC 81.36
  • GERN 17.86

About MRC MRC Global Inc.

MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: